Integer Holdings stock barely budged today, up about 0.5% and extending a steady three month climb, even though the latest quarter quietly rewired the earnings story. The medical device manufacturer turned in Q2 basic earnings per share of about US$0.69 on revenue of roughly US$464 million. The real headline sits in the trailing 12 month picture, where net margin stands at 7% and earnings from continuing operations total about US$128 million. For anyone thinking beyond this week’s chart, the key question is whether that profitability level looks sustainable against the company’s debt load.

Love Integer Holdings' 7% net margin but concerned about how that earnings base stacks up against its debt load? Take a look at our list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$464.11 million vs. US$476.49 million (modest decline year on year)
• Net Income, Q2 2026 vs. Q2 2025: US$23.61 million vs. US$37.01 million (decline year on year)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.69 vs. US$1.06 (decline year on year)
• Net Margin, Trailing 12 Months vs. Prior Year: 7.0% vs. 4.7% (improved profitability on a trailing basis)

Prefer clear charts instead of another dense block of earnings figures? See Integer Holdings' full visual breakdown, including its valuation picture, in our company report for Integer Holdings.

Integer bullish thesis meets mixed execution reality

Bulls argue that Integer Holdings is a high quality medical device CDMO with improving margins and a richer product mix that can steadily compound earnings. The Q2 print partly backs that up. Trailing 12 month net margin at 7.0% versus 4.7% in the prior year shows the margin improvement story is real at the consolidated level. Adjusted EPS of US$1.60 also cleared expectations, helped by cost control and demand across medical device lines. However, revenue of US$464.1 million declined 2.6% year on year and cardio & vascular revenue of US$280.3 million also fell. That undercuts the idea of clean volume led growth from the pipeline. The KKR take private at US$127 per share confirms that a financial buyer sees value in the platform, but with guidance withdrawn and no earnings call, investors lose a key milestone for tracking whether new launches are replacing weaker programs in real time.

Bearish concerns on growth and risk get support

Bears focus on soft organic growth, program attrition and deal related risk that may outweigh Integer Holdings' margin gains. The latest quarter gives that view plenty of support. Headline revenue is down year on year and cardio & vascular, which should benefit from aging demographics, is also lower. That aligns with earlier comments that exits in portable medical and a major neuromodulation program are a real drag. Q1 guidance was already cut, and now management has fully withdrawn guidance and cancelled the earnings call after the KKR deal. That removes forward milestones on demand timing and contract durability. FX and macro sensitivity remain live issues, with no offset from faster growth in disclosed segments. The law firm investigation adds another overhang during a period when transaction execution is the main path to value, which fits the bearish focus on legal and closing risk rather than clean operational upside.

After guidance withdrawal, soft revenue and debt coverage concerns, are these issues isolated or part of deeper structural problems? Review the risk analysis for Integer Holdings which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If Integer Holdings' 7% trailing net margin and the recent guidance withdrawal have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the story evolves. Once you are invested, use the Portfolio Command Center to cut through day to day noise and focus on the key fundamental updates that matter for your holdings. For a wider view, tap into crowd insights through the Community and see how other investors are interpreting the same data. By spotting potential catalysts and risks early, you give yourself a better chance to stay ahead of the market.

Seeking Fresh Alternatives Beyond Integer Holdings

Some stocks start breaking out while others lose momentum fast. Use fresh ideas under the radar for now to spot potential winners before the crowd catches up, and consider acting while these opportunities are still less widely followed.

• Explore potential steady cash generators by reviewing companies in the 7 dividend fortresses while yields remain elevated and prices have not fully reflected their balance sheet strength.
• Scan for potential future infrastructure candidates with the 36 power grid technology and infrastructure stocks before the story spreads and more capital focuses on these grid and electrification names.
• Look for possible growth leaders in automation by checking the 36 robotics and automation stocks while industrial adoption trends are still being incorporated into broader market expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.